Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Harrison

Showing results (51-60 of 153) with videos related to

Pageof 16
Sort By:
Bone Marrow Transplantation|March 30, 2022
The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myelomaMatthew J Rees, Ashish Panigrahi, Simon J Harrison, et al.
Haematologica|September 28, 2023
Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapyMika Casey, Carol Lee, Wing Yu Kwok, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 12, 2013
Low uptake of upfront autologous transplantation for myeloma in a jurisdiction with universal health care coverage: a population-based patterns of care study in AustraliaNicole Wong Doo, Michael Coory, Victoria White, et al.
Journal of Translational Medicine|September 8, 2016
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myelomaRachel E Cooke, Nicholas A Gherardin, Simon J Harrison, et al.
Hematological Oncology|December 7, 2011
Emergence of central nervous system myeloma in the era of novel agentsShane A Gangatharan, Dennis A Carney, H Miles Prince, et al.
Annals of Hematology|July 28, 2018
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipientsAbbey Willcox, Eric Wong, Christa Nath, et al.
Future Oncology (London, England)|September 15, 2021
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM studyPaul G Richardson, Simon J Harrison, Sara Bringhen, et al.
British Journal of Haematology|June 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)Andrew Spencer, Anna Kalff, Jake Shortt, et al.
BMC Medicine|March 5, 2014
A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patientsSuribabu Gudipati, Evangelos M Fragkakis, Vincenzo Ciriello, et al.
Haematologica|October 12, 2014
Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapiesBenjamin W Teh, Jasmine C Teng, Karin Urbancic, et al.
Pageof 16

Showing results (51-60 of 153) with videos related to

Sort By:
Pageof 16
Bone Marrow Transplantation|March 30, 2022
The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myelomaMatthew J Rees, Ashish Panigrahi, Simon J Harrison, et al.
Haematologica|September 28, 2023
Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapyMika Casey, Carol Lee, Wing Yu Kwok, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 12, 2013
Low uptake of upfront autologous transplantation for myeloma in a jurisdiction with universal health care coverage: a population-based patterns of care study in AustraliaNicole Wong Doo, Michael Coory, Victoria White, et al.
Journal of Translational Medicine|September 8, 2016
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myelomaRachel E Cooke, Nicholas A Gherardin, Simon J Harrison, et al.
Hematological Oncology|December 7, 2011
Emergence of central nervous system myeloma in the era of novel agentsShane A Gangatharan, Dennis A Carney, H Miles Prince, et al.
Annals of Hematology|July 28, 2018
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipientsAbbey Willcox, Eric Wong, Christa Nath, et al.
Future Oncology (London, England)|September 15, 2021
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM studyPaul G Richardson, Simon J Harrison, Sara Bringhen, et al.
British Journal of Haematology|June 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)Andrew Spencer, Anna Kalff, Jake Shortt, et al.
BMC Medicine|March 5, 2014
A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patientsSuribabu Gudipati, Evangelos M Fragkakis, Vincenzo Ciriello, et al.
Haematologica|October 12, 2014
Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapiesBenjamin W Teh, Jasmine C Teng, Karin Urbancic, et al.
Pageof 16